A5087170219- Glioma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Mathematical Biology Tumor Growth
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- Cancer Treatment and Pharmacology
- Brain Metastases and Treatment
- Medical Imaging Techniques and Applications
- Cancer Genomics and Diagnostics
- Histone Deacetylase Inhibitors Research
- Immune cells in cancer
- Ferroptosis and cancer prognosis
- Cancer Research and Treatments
- Colorectal Cancer Treatments and Studies
- Management of metastatic bone disease
- Angiogenesis and VEGF in Cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Global Health Care Issues
- Protein Degradation and Inhibitors
- Cell Image Analysis Techniques
- Microtubule and mitosis dynamics
- Meningioma and schwannoma management
- Neuroblastoma Research and Treatments
- HER2/EGFR in Cancer Research
Copenhagen University Hospital
2010-2025
Rigshospitalet
2007-2024
University of Copenhagen
2010-2021
The aim of this clinical trial was to investigate safety and efficacy when combining cetuximab with bevacizumab irinotecan in patients recurrent primary glioblastoma multiforme (GBM). Patients were included GBM progression within 6 months ending standard treatment (radiotherapy temozolomide). Bevacizumab administered IV every 2 weeks. first 10 received 5 mg/kg, but increased mg/kg after interim analysis. Irinotecan dose based on whether taking enzyme-inducing antiepileptic drugs or not: 340...
We retrospectively determined the efficacy and safety of a combination bevacizumab irinotecan in consecutive series 52 heavily pre-treated patients with recurrent high-grade brain tumours. Patients received (10 mg/kg) [340 mg/m(2) for those receiving enzyme-inducing antiepileptic drugs (EIAEDs) 125 not EIAEDs] every 2 weeks. Fifty-two were included 47 evaluable response.Complete or partial response was observed 25% all cases (30% grade IV glioma 15% III glioma). Estimated median...
Abstract Background: Glioblastoma (GBM), the most aggressive brain tumor, is treated with surgery, chemotherapy, and radiation, yet 90% recur within two years. PD-1 blockade improves outcomes in other cancers, but shows limited effect GBM, likely due to tumor heterogeneity an immunosuppressive microenvironment. This study aims investigate post-treatment transcriptional changes cells tumor-associated macrophages (TAMs) matched primary recurrent focusing on neoadjuvant blockade. Methods: We...
Abstract Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis. Although immunotherapy being explored as a potential treatment option for patients GBM, it unclear whether systemic can reach and modify the microenvironment in brain. We evaluated immune characteristics receiving anti-PD-1 checkpoint inhibitor nivolumab 1 week prior to surgery, compared control salvage resection without treatment. observed saturating levels of bound intratumorally tissue-resident T cells brain,...
Abstract Background In 2016, genomic profiling was implemented for patients with grade 4 primary brain tumors at Rigshospitalet, Denmark. The aim of this study to discover actionable alterations and match these targeted therapies. Methods Between January 2016 December 2023, 483 tumor were profiled. We retrieved clinical data molecular data. Whole exome, whole genome, or panel sequencing, along SNP array analyses, RNA-seq performed on resected tissue. Alterations classified according the...
Several recent studies have demonstrated a beneficial effect of anti-angiogenic treatment with the vascular endothelial growth factor-neutralizing antibody bevacizumab in recurrent high-grade glioma. In current study, immunohistochemical evaluation biomarkers involved angiogenesis, hypoxia and mediators epidermal factor receptor (EGFR) pathway were investigated. Tumor tissue was obtained from previous phase II treating primary glioblastoma multiforme (GBM) patients EGFR inhibitor cetuximab...
Background Glioblastoma patients administered standard therapies, comprising maximal surgical resection, radiation therapy with concomitant and adjuvant temozolomide, have a variable prognosis median overall survival of 15–16 months 2-year 30%. The aim this study was to develop prognostic nomogram for glioblastoma treated outside clinical trials. Methods included 680 consecutive, non-selected as primary treatment between the years 2005 2016 at Rigshospitalet, Copenhagen, Denmark. model...
Overexpression and/or amplification of the epidermal growth factor receptor (EGFR) is present in 35–45% primary glioblastoma multiforme tumors and has been correlated with a poor prognosis. In this study, we investigated effect cetuximab intracellular signaling pathways downstream EGFR, important for cell survival proliferation. We show insufficient EGFR downregulation competition endogenous ligands upon treatment. Dose–response experiments showed inhibition phosphorylation without affecting...
Both amino acid positron emission tomography (PET) and magnetic resonance imaging (MRI) blood volume (BV) measurements are used in suspected recurrent high-grade gliomas. We compared the separate combined diagnostic yield of simultaneously acquired dynamic contrast-enhanced (DCE) perfusion MRI O-(2-[18F]-fluoroethyl)-L-tyrosine ([18F]FET) PET patients with anaplastic astrocytoma glioblastoma following standard therapy.A total 76 lesions 60 hybrid [18F]FET PET/MRI scans DCE from recurrence...
Abstract Spinal ependymoma (EPN) with MYCN-amplification (SP-EPN-MYCN) was recently recognized as a distinct tumor type within the 2021 WHO classification of CNS tumors. To date, information about epidemiological, clinical, and biological features SP-EPN-MYCN remain sparse. Using DNA-methylation profiling, we collected cohort n = 71 (54 primaries, 17 relapses) SP-EPN-MYCNs. Based on Heidelberg Methylation Brain Tumor Classifier V12.5, 95.6% (68/71) reached classifier score ≥ 0.9. In 68/71...
2056 Background: Recent data has shown that bevacizumab (B) and irinotecan (I) induces significant responses in recurrent GBM. Primary GBM is very often associated with amplification of EFGR (40–50%) alterations the EGFR gene. In vivo experiments have cetuximab (C) increases apoptosis, decreases cell proliferation decrease vascular endothelial growth factor expression EGFR-amplified cells vitro. The use combination C I a significantly higher response rate compared to as monotherapy...
12503 Background: The prognosis of recurrent malignant brain tumors is poor, and no efficacious therapy exists in patients previously treated with radiotherapy standard chemotherapy. Bevacizumab (B) binds to VEGF inhibits tumor angiogenesis, treatment this drug might induce regression prolongation life. Irinotecan (I) a topoisomerase 1 inhibitor modest effect on primary tumors. combination B I gliomas was presented at ASCO 2006 showed very encouraging responses. Methods: We report...
<p>Verification of detected NARTs.</p>
<p>Supplementary Figure 9 Co-expression of Inhibitory molecules on intratumoral T cells.</p>
<p>Tumor-reactive TILs.</p>
<p>Intratumoral cell populations identified from transcriptomic data.</p>
<p>Presentation of patients included in CA209-9UP.</p>
<p>Intratumoral cell populations identified from transcriptomic data.</p>
<p>HLA expression on live cells in tumor digest</p>
<p>Detection of NARTs in YTILs, REP TILs and ex vivo PBMCs</p>
<p>Progression free survival and overall related for NIVO CTRL patients.</p>
<p>Progression free survival and overall related to frequency of CD8+ T-cells expressing CD28.</p>